Business Context and Reporting Period
Company: DiaMedica Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 12, 2025
Reporting Period: Single event date (August 12, 2025)
The Company entered into a Sales Agreement with TD Securities (USA) LLC ("TD Cowen") to establish an "at-the-market" (ATM) equity offering program.
Key Financial Metrics
This filing does not contain audited financial statements, revenue, profit, cash flow, or debt metrics. The primary financial data points relate to the new financing facility:
- Maximum Offering Amount: Up to $100.0 million in Common Shares.
- Compensation to Agent: Up to 3.0% of gross proceeds from shares sold.
- Trading Symbol: DMAC (Nasdaq Stock Market LLC).
Material Changes
The material change reported is the execution of the Sales Agreement, enabling the Company to sell Common Shares from time to time through TD Cowen as sales agent. No sales have occurred as of the filing date; the agreement establishes the framework for future capital raises.
Guidance, Outlook, and Risks
- Regulatory Status: The ATM Shares will be issued pursuant to a shelf registration statement on Form S-3 filed on August 12, 2025. The filing text states the registration statement has not yet been declared effective by the SEC, and no sales may be made until effectiveness is declared.
- Proceeds Uncertainty: Actual proceeds depend on the number of shares sold and the offering price at the time of sale. TD Cowen is not required to sell any specific number or dollar amount of securities.
- Legal Opinions: Legal opinions regarding the shares were issued by Pushor Mitchell and Alston & Bird LLP.
Investor Verification Checklist
- Verify the effectiveness status of the Form S-3 shelf registration statement (File No. 333-[_]) to confirm when sales can commence.
- Monitor future prospectus supplements for the specific number of shares sold and actual proceeds received.
- Review the Company's current cash position and burn rate to assess the necessity and timing of utilizing the $100.0 million facility.
- Check for any subsequent filings regarding the actual execution of share sales under the ATM program.